Company Filing History:
Years Active: 2004
Title: Innovator Spotlight: Sunila Piplani from Mountain View, CA
Introduction
Sunila Piplani is an accomplished inventor based in Mountain View, California, known for her groundbreaking work in pharmaceuticals. As a prominent member of Affymax, Inc., she has made significant contributions to the field, particularly in relation to the granulocyte-colony stimulating factor receptor (G-CSFR).
Latest Patents
Sunila holds a notable patent for "Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses." This invention features novel compounds that bind to the G-CSFR, characterized by a peptide chain ranging from 6 to 40 amino acids in length. The compounds are valuable as probes for affinity screening and have been shown to exhibit agonist or antagonist activity, making them beneficial in treating conditions associated with a low white blood cell count. Additionally, pharmaceutical compositions and methods of use derived from her research further enhance its applicability in medical treatments.
Career Highlights
Throughout her career, Sunila has demonstrated exceptional expertise in the pharmaceutical sciences and biotechnology sectors. Her role at Affymax, Inc. has positioned her as a key player in the development of innovative treatments aimed at improving patient outcomes.
Collaborations
Sunila has collaborated with several esteemed colleagues, including Steven E. Cwirla and Palani Balu. Together, they have worked on advancing research initiatives that further the understanding and application of G-CSFR targeting technologies. This teamwork exemplifies the collaborative spirit present in the field of innovation and drug development.
Conclusion
With her inventive contributions and dedication to advancing medical science, Sunila Piplani stands out as a significant figure in her field. Her patent showcases her ability to innovate solutions that address critical health challenges, reaffirming her status as an influential inventor in the ever-evolving world of pharmaceuticals.